This is a working overview of tesamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-07 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Grow Papaver Somniferum from vizyonpara.com Comprehensive profile for Papaver somniferum from MaltaWildPlants.com Opium FAQ v1.0 from Opioids.com Opium Poppy Cultivation and Heroin Processing in Southeast Asia from the School of Pacific and Asian Studies "Downward Spiral – Banning Opium in Afghanistan and Burma", Transnational Institute TNI, Debate Paper, June 2005 "Withdrawal Symptoms in the Golden Triangle – A Drugs Market in Disarray" TNI Paper by Tom Kramer et al. Chouvy P.A., 2009, "Opium. Uncovering the Politics of the Poppy", London, I.B. Tauris (Cambridge, Harvard University Press: 2010)
Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer. Lurbinectedin is a synthetic tetrahydropyrrolo [4,3,2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death. The most common side effects include leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhea. Lurbinectedin was approved for medical use in the United States in June 2020.
== Background == Discoveries by Frederick Griffith and improved on by Oswald Avery discovered that the substance responsible for producing inheritable change in the disease-causing bacteria (Streptococcus pneumoniae) was neither a protein nor a lipid, rather deoxyribonucleic acid (DNA). In 1944, he and his colleagues Colin MacLeod and Maclyn McCarty suggested that DNA was responsible for transferring genetic information. Later, Erwin Chargaff (1950) discovered that the makeup of DNA differs from one species to another. These experiments helped pave the way for the discovery of the structure of DNA. In 1953, with the help of Maurice Wilkins and Rosalind Franklin's X-ray crystallography, James Watson and Francis Crick proposed DNA is structured as a double helix. In the 1960s, one main DNA mystery scientists needed to figure out was the number of bases found in each code word, or codon, during transcription. Scientists knew there was a total of four bases (guanine, cytosine, adenine, and thymine). They also knew that were 20 known amino acids. George Gamow suggested that the genetic code was made of three nucleotides per amino acid. He reasoned that because there are 20 amino acids and only four bases, the coding units could not be single (4 combinations) or pairs (only 16 combinations). Rather, he thought triplets (64 possible combinations) were the coding unit of the genetic code. However, he proposed that the triplets were overlapping and non-degenerate (later explained by Crick in his Wobble concept).
Gallium nitrate is used to treat the side effects of cancer; gallium citrate, a radiopharmaceutical, facilitates imaging of inflamed body areas. Selenium sulfide is used in medicinal shampoos and to treat skin infections such as tinea versicolor. Iodine is used as a disinfectant in various forms. Bismuth is an ingredient in some antibacterials.
Sources: en.wikipedia.org
A statistician who has a combination of education/training and experience sufficient to implement the principles in this guidance and who is responsible for the statistical aspects of the trial. (ICH E9) t-test
Defatted soy flour is obtained from solvent extracted flakes and contains less than 1% oil. "Natural or full-fat soy flour is made from unextracted, dehulled beans and contains about 18% to 20% oil." Its high oil content requires the use of a specialized Alpine Fine Impact Mill to grind rather than the usual hammer mill. Full-fat soy flour has a lower protein concentration than defatted flour. Extruded full-fat soy flour, ground in an Alpine mill, can replace/extend eggs in baking and cooking. Full-fat soy flour is a component of Cornell bread. Low-fat soy flour is made by adding some oil back into defatted soy flour. Fat levels range from 4.5% to 9%. High-fat soy flour can also be produced by adding back soybean oil to defatted flour, usually at 15%. Soy lecithin can be added (up to 15%) to soy flour to make lecithinated soy flour. It increases dispersibility and gives it emulsifying properties. Soy flour has 50% protein and 5% fiber. It has higher levels of protein, thiamine, riboflavin, phosphorus, calcium, and iron than wheat flour. It does not contain gluten. As a result, yeast-raised breads made with soy flour are dense in texture. Among many uses, soy flour thickens sauces, prevents staling in baked food, and reduces oil absorption during frying. Baking food with soy flour gives it tenderness, moistness, a rich color, and a fine texture. Soy grits are similar to soy flour, except the soybeans have been toasted and cracked into coarse pieces. Kinako is a soy flour used in Japanese cuisine. Section reference: Circle & Smith (1972, p. 442)
In addition to tracks from all of their studio albums, the box set contains live tracks dating back to 1974 through the band's final show in 2015, and also marked the first time that their 1973 debut single "Not Fade Away" and its B-side "You Can't Fight It" were made available on any other format. Upon the release of Rush 50, concerns emerged over the authenticity and artistic value of the artwork, as Rush fans widely speculated art director Hugh Syme may have created the Rush 50 artwork using generative artificial intelligence tools.
"Lobotomy's back" : 1997 article on cingulotomy in Discover magazine "Leucotomy: a qualified defence of ‘then’": 2001 article in QJM by psychiatrist John Sutton Pippard "My Lobotomy": 2005 Soundportraits.org interview with Sallie Ellen Ionesco, the first recipient of a lobotomy in 1946 "'My Lobotomy': Howard Dully's Journey": 2005 interview with the author of My Lobotomy "Mental Cruelty": 2006 Sunday Times article on lobotomy and contemporary psychosurgery in the United Kingdom "Nobel Panel Urged to Rescind Prize for Lobotomies": 2005 article on the Nobel Prize in Physiology or Medicine awarded to Egas Moniz "Ten Notable Lobotomies": 2009 compilation of biographies of lobotomy patients in Listverse The Lobotomists: 2011 BBC Radio 4 documentary on the history of lobotomy
This means the urethra, a compressible tube used for urination, runs through the middle of the prostate; enlargement of the prostate can constrict the urethra so that urinating becomes slow and painful. Prostatic secretions vary among species. They are generally composed of simple sugars and are often slightly alkaline. In eutherian mammals, these secretions usually contain fructose. The prostatic secretions of marsupials usually contain N-Acetylglucosamine or glycogen instead of fructose.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.